Premium
Acute leukemias with ETV6/ABL1 ( TEL/ABL ) fusion: Poor prognosis and prenatal origin
Author(s) -
Zuna Jan,
Zaliova Marketa,
Muzikova Katerina,
Meyer Claus,
Lizcova Libuse,
Zemanova Zuzana,
Brezinova Jana,
Votava Felix,
Marschalek Rolf,
Stary Jan,
Trka Jan
Publication year - 2010
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/gcc.20796
Subject(s) - etv6 , abl , medicine , myeloid leukemia , fusion gene , leukemia , minimal residual disease , pediatrics , oncology , immunology , chromosomal translocation , biology , gene , genetics , receptor , tyrosine kinase
The ETV6/ABL1 ( TEL/ABL ) fusion gene is a rare aberration in malignant disorders. Only 19 cases of ETV6/ABL1 ‐positive hematological malignancy have been published, diagnosed with chronic myeloid leukemia, other types of chronic myeloproliferative neoplasm, acute myeloid leukemia or acute lymphoblastic leukemia (ALL). This study reports three new cases (aged 8 months, 5 years, and 33 years) of ALL with the ETV6/ABL1 fusion found by screening 392 newly diagnosed ALL patients (335 children and 57 adults). A thorough review of the literature and an analysis of all published data, including the three new cases, suggest poor prognosis of ETV6/ABL1 ‐positive acute leukemias. The course of the disease in the two pediatric patients is characterized by minimal residual disease monitoring, using quantification of both the ETV6/ABL1 transcript and immunoreceptor gene rearrangements. Eosinophilia could not be confirmed as a hallmark of the ETV6/ABL1 ‐positive disease. Studies of neonatal blood spots demonstrated that, in the child diagnosed at five years, the ETV6/ABL1 fusion initiating the ALL originated prenatally. © 2010 Wiley‐Liss, Inc.